The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition

  1. Jeremy L Praissman
  2. Tobias Willer
  3. M Osman Sheikh
  4. Ants Toi
  5. David Chitayat
  6. Yung-Yao Lin
  7. Hane Lee
  8. Stephanie H Stalnaker
  9. Shuo Wang
  10. Pradeep Kumar Prabhakar
  11. Stanley F Nelson
  12. Derek L Stemple
  13. Steven A Moore
  14. Kelley W Moremen
  15. Kevin P Campbell
  16. Lance Wells  Is a corresponding author
  1. University of Georgia, United States
  2. University of Iowa, United States
  3. Mount Sinai Hospital, Canada
  4. University of Toronto, Canada
  5. Blizard Institute, United Kingdom
  6. University of California, Los Angeles, United States
  7. Wellcome Trust Sanger Institute, United Kingdom

Abstract

Multiple glycosyltransferases are essential for the proper modification of alpha-dystroglycan, as mutations in the encoding genes cause congenital/limb-girdle muscular dystrophies. Here we elucidate further the structure of an O-mannose-initiated glycan on alpha-dystroglycan that is required to generate its extracellular matrix-binding polysaccharide. This functional glycan contains a novel ribitol structure that links a phosphotrisaccharide to xylose. ISPD is a CDP-ribitol (ribose) pyrophosphorylase that generates the reduced sugar nucleotide for the insertion of ribitol in a phosphodiester linkage to the glycoprotein. TMEM5 is a UDP-xylosyl transferase that elaborates the structure. We demonstrate in a zebrafish model as well as in a human patient that defects in TMEM5 result in muscular dystrophy in combination with abnormal brain development. Thus, we propose a novel structure - a ribitol in a phosphodiester linkage - for the moiety on which TMEM5, B4GAT1, and LARGE act to generate the functional receptor for ECM proteins having LG domains.

Article and author information

Author details

  1. Jeremy L Praissman

    Complex Carbohydrate Research Center, University of Georgia, Athens, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Tobias Willer

    Department of Molecular Physiology and Biophysics, Neurology, and Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. M Osman Sheikh

    Complex Carbohydrate Research Center, University of Georgia, Athens, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Ants Toi

    Department of Medical Imaging, Mount Sinai Hospital, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  5. David Chitayat

    Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, University of Toronto, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  6. Yung-Yao Lin

    Blizard Institute, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Hane Lee

    Department of Human Genetics, Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Stephanie H Stalnaker

    Complex Carbohydrate Research Center, University of Georgia, Athens, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Shuo Wang

    Complex Carbohydrate Research Center, University of Georgia, Athens, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Pradeep Kumar Prabhakar

    Complex Carbohydrate Research Center, University of Georgia, Athens, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Stanley F Nelson

    Department of Human Genetics, Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Derek L Stemple

    Wellcome Trust Genome Campus, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Steven A Moore

    Department of Pathology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Kelley W Moremen

    Complex Carbohydrate Research Center, Department of Biochemistry and Molecular Biology, University of Georgia, Athens, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Kevin P Campbell

    Department of Molecular Physiology and Biophysics, Neurology, and Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Lance Wells

    Complex Carbohydrate Research Center, University of Georgia, Athens, United States
    For correspondence
    lwells@ccrc.uga.edu
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Human subjects: Informed consent and ethical approval is detailed in the Materials and Methods section. All tissues and patient cells were obtained and tested according to the guidelines set out by the Human Subjects Institutional Review Board of the University of Iowa; informed consent was obtained from all subjects or their legal guardians.

Copyright

© 2016, Praissman et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,485
    views
  • 825
    downloads
  • 95
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jeremy L Praissman
  2. Tobias Willer
  3. M Osman Sheikh
  4. Ants Toi
  5. David Chitayat
  6. Yung-Yao Lin
  7. Hane Lee
  8. Stephanie H Stalnaker
  9. Shuo Wang
  10. Pradeep Kumar Prabhakar
  11. Stanley F Nelson
  12. Derek L Stemple
  13. Steven A Moore
  14. Kelley W Moremen
  15. Kevin P Campbell
  16. Lance Wells
(2016)
The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition
eLife 5:e14473.
https://doi.org/10.7554/eLife.14473

Share this article

https://doi.org/10.7554/eLife.14473

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Katherine A Senn, Karli A Lipinski ... Aaron A Hoskins
    Research Article

    Pre-mRNA splicing is catalyzed in two steps: 5ʹ splice site (SS) cleavage and exon ligation. A number of proteins transiently associate with spliceosomes to specifically impact these steps (first and second step factors). We recently identified Fyv6 (FAM192A in humans) as a second step factor in Saccharomyces cerevisiae; however, we did not determine how widespread Fyv6’s impact is on the transcriptome. To answer this question, we have used RNA sequencing (RNA-seq) to analyze changes in splicing. These results show that loss of Fyv6 results in activation of non-consensus, branch point (BP) proximal 3ʹ SS transcriptome-wide. To identify the molecular basis of these observations, we determined a high-resolution cryo-electron microscopy (cryo-EM) structure of a yeast product complex spliceosome containing Fyv6 at 2.3 Å. The structure reveals that Fyv6 is the only second step factor that contacts the Prp22 ATPase and that Fyv6 binding is mutually exclusive with that of the first step factor Yju2. We then use this structure to dissect Fyv6 functional domains and interpret results of a genetic screen for fyv6Δ suppressor mutations. The combined transcriptomic, structural, and genetic studies allow us to propose a model in which Yju2/Fyv6 exchange facilitates exon ligation and Fyv6 promotes usage of consensus, BP distal 3ʹ SS.

    1. Biochemistry and Chemical Biology
    2. Neuroscience
    Eyal Paz, Sahil Jain ... Abdussalam Azem
    Research Article

    TIMM50, an essential TIM23 complex subunit, is suggested to facilitate the import of ~60% of the mitochondrial proteome. In this study, we characterized a TIMM50 disease-causing mutation in human fibroblasts and noted significant decreases in TIM23 core protein levels (TIMM50, TIMM17A/B, and TIMM23). Strikingly, TIMM50 deficiency had no impact on the steady-state levels of most of its putative substrates, suggesting that even low levels of a functional TIM23 complex are sufficient to maintain the majority of TIM23 complex-dependent mitochondrial proteome. As TIMM50 mutations have been linked to severe neurological phenotypes, we aimed to characterize TIMM50 defects in manipulated mammalian neurons. TIMM50 knockdown in mouse neurons had a minor effect on the steady state level of most of the mitochondrial proteome, supporting the results observed in patient fibroblasts. Amongst the few affected TIM23 substrates, a decrease in the steady state level of components of the intricate oxidative phosphorylation and mitochondrial ribosome complexes was evident. This led to declined respiration rates in fibroblasts and neurons, reduced cellular ATP levels, and defective mitochondrial trafficking in neuronal processes, possibly contributing to the developmental defects observed in patients with TIMM50 disease. Finally, increased electrical activity was observed in TIMM50 deficient mice neuronal cells, which correlated with reduced levels of KCNJ10 and KCNA2 plasma membrane potassium channels, likely underlying the patients’ epileptic phenotype.